Research library
Alumis Inc. (ALMS): the bull case and the bear case
Alumis Inc. · NASDAQ · Equity · Stock
The synthesis
Phase 3 psoriasis data and a Q4 NDA filing provide a clear regulatory path offset by a significant Phase 2b trial failure in lupus.
- Pivotal Phase 3 momentum
The company reported positive topline results for pivotal Phase 3 ONWARD1 and ONWARD2 trials for envu in psoriasis, with a New Drug Application submission planned for Q4 2026.
- Precision medicine pivot
Management identified robust responses in a specific patient subgroup during the Phase 2b SLE trial, providing a targeted pathway for late-stage development despite the broader population miss (8-K Item 8.01, 2026-09-01).
- Strong unit economics
The company maintains an 88.2% gross margin, suggesting high-value chemistry and efficient underlying product potential as it transitions from clinical stages toward commercialization.
- Oversold technical profile
Technical indicators suggest the stock is significantly oversold, with the Stochastic %K at 11.2 and the price trading more than 60% below its 50-day moving average of $26.46.
- Major clinical setback
The Phase 2b trial for systemic lupus erythematosus failed to meet both primary and secondary endpoints, creating significant uncertainty regarding the drug's broader market potential.
- Extreme cash burn
Operating margins of -6204.4% reflect massive R&D spending relative to revenue, and the 10-Q notes the company will require substantial additional financing to achieve its goals.
- Heavy reliance on third parties
Per the 10-Q, Alumis relies heavily on third-party manufacturers and CROs, which introduces significant supply chain and quality risks during the critical transition to Phase 3.
Catalysts
- NDA submission for envu in PsO Q4 2026
- Phase 3 lupus study initiation Near-term
- Lonigutamab pipeline update Ongoing
- Quarterly earnings release Nov 2026
Risks
- Clinical trial failure Primary/Secondary miss
- Capital requirements Substantial financing needed
- Regulatory rejection NDA Q4 2026
- Market concentration TYK2 inhibitor focus
What would change the view
A successful NDA acceptance by the FDA for envu in psoriasis would significantly de-risk the commercial thesis and validate the lead asset. Conversely, any further delays in the subgroup-specific lupus Phase 3 trial or a failure to secure additional financing on favorable terms would likely accelerate the current bearish technical trend.
Insider activity
Open-market purchases and sales reported by company insiders on SEC Form 4, from EDGAR. Share counts and dates only.
Trailing 3 months: 0 open-market purchases by 0 insiders and 7 sales by 6 insiders. Net selling (Strong — 6 insiders selling).
| Insider | Role | Side | Shares | Trade date | Filing |
|---|---|---|---|---|---|
| Pangali Sanam | Officer · Chief Legal Officer | Sale | 5,000 | 2026-07-06 | Form 4 |
| Schroer John R. | Officer · Chief Financial Officer | Sale | 3,282 | 2026-08-03 | Form 4 |
| Hardiman Roy C. | Officer · Chief Business & Strategy Ofcr | Sale | 2,692 | 2026-08-03 | Form 4 |
| Goldstein David M | Officer · Chief Scientific Officer | Sale | 2,596 | 2026-08-03 | Form 4 |
| Bradley Mark Christopher | Officer · Chief Development Officer | Sale | 2,572 | 2026-08-03 | Form 4 |
Sources
- FMP · ALMS daily prices and technical indicators Analyst note
- FMP · ALMS financial statements (income / balance / cash flow) SEC filing
- SEC EDGAR · ALMS full-text filing search SEC filing
- SEC · 8-K filed 2026-09-01 (Items 8.01, 9.01) SEC filing · 8-K · 2026-09-01
- SEC · SCHEDULE 13D filed 2026-08-17 SEC filing · SCHEDULE 13D · 2026-08-17
- SEC · 10-Q filed 2026-08-13 SEC filing · 10-Q · 2026-08-13
- SEC · 8-K filed 2026-08-13 (Items 2.02, 9.01) SEC filing · 8-K · 2026-08-13
- SEC · 8-K filed 2026-08-10 (Items 8.01, 9.01) SEC filing · 8-K · 2026-08-10
- SEC · SCHEDULE 13G filed 2026-08-06 SEC filing · SCHEDULE 13G · 2026-08-06
- SEC · 4 filed 2026-08-05 SEC filing · 4 · 2026-08-05
- SEC · 4 filed 2026-08-05 SEC filing · 4 · 2026-08-05
- SEC · 4 filed 2026-08-05 SEC filing · 4 · 2026-08-05
- SEC · 4 filed 2026-08-05 SEC filing · 4 · 2026-08-05
- SEC · 4 filed 2026-08-05 SEC filing · 4 · 2026-08-05
- SEC · 4 filed 2026-08-05 SEC filing · 4 · 2026-08-05
- SEC · SCHEDULE 13G filed 2026-07-27 SEC filing · SCHEDULE 13G · 2026-07-27
- SEC · 4 filed 2026-07-08 SEC filing · 4 · 2026-07-08
- SEC · 144 filed 2026-07-06 SEC filing · 144 · 2026-07-06
- SEC · 4 filed 2026-07-02 SEC filing · 4 · 2026-07-02
- SEC · 4 filed 2026-07-02 SEC filing · 4 · 2026-07-02
- SEC · 4 filed 2026-07-02 SEC filing · 4 · 2026-07-02
- SEC · 4 filed 2026-07-02 SEC filing · 4 · 2026-07-02
- SEC · 4 filed 2026-07-02 SEC filing · 4 · 2026-07-02
- SEC · SCHEDULE 13D/A filed 2026-07-02 SEC filing · SCHEDULE 13D/A · 2026-07-02
- SEC · 8-K filed 2026-07-02 (Items 5.07) SEC filing · 8-K · 2026-07-02
- SEC · 8-K filed 2026-06-29 (Items 8.01, 9.01) SEC filing · 8-K · 2026-06-29
- Reuters · Alumis eyes late-stage lupus study despite trial miss News
- GlobeNewsWire · Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) News
Read the full analysis in the app
This page publishes the written thesis. The app adds the sections not published here:
- Fundamentals
- Technicals
- News with bull, bear, and neutral tags
- 7-day news sentiment and earnings-call tone
- Forward analyst estimates
